NeoGenomics Stock Price and Value Analysis

Should you buy NeoGenomics stock? (NasdaqCM:NEO). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
None.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company is not making money.
  • This company pays no dividend.

NEO Free Cash Flow Trend

Hmm, we can't give any reliable projection for NeoGenomics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for NEO
Free Cash Flow trendline for NeoGenomics

Inside the NEO Numbers

NEO Price
(NeoGenomics stock price per share)
$19.66
[?] PE Ratio versus Sector 4824% higher than other Healthcare stocks
[?] PE Ratio versus Industry 392% higher than other Diagnostics & Research stocks
[?] Free Cash Flow Jitter 45%

Is NeoGenomics Stock on Sale?

Based on our analysis, we believe that you should not buy NeoGenomics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy NEO Stock?

Does NeoGenomics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.